Last reviewed · How we verify

OnabotulinumtoxinA 145 UNT [Botox]

Beth Israel Deaconess Medical Center · FDA-approved active Small molecule

OnabotulinumtoxinA 145 UNT [Botox] is a Botulinum toxin Small molecule drug developed by Beth Israel Deaconess Medical Center. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Strabismus. Also known as: BOTOX.

OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.

At a glance

Generic nameOnabotulinumtoxinA 145 UNT [Botox]
Also known asBOTOX
SponsorBeth Israel Deaconess Medical Center
Drug classBotulinum toxin
TargetSNAP-25 (synaptosome-associated protein of 25 kDa)
ModalitySmall molecule
Therapeutic areaNeurology, Dermatology, Aesthetics
PhaseFDA-approved

Mechanism of action

The drug is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle release. This prevents neurotransmitter signaling at the neuromuscular junction, resulting in flaccid paralysis of targeted muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and muscle function returns.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about OnabotulinumtoxinA 145 UNT [Botox]

What is OnabotulinumtoxinA 145 UNT [Botox]?

OnabotulinumtoxinA 145 UNT [Botox] is a Botulinum toxin drug developed by Beth Israel Deaconess Medical Center, indicated for Cervical dystonia, Blepharospasm, Strabismus.

How does OnabotulinumtoxinA 145 UNT [Botox] work?

OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

What is OnabotulinumtoxinA 145 UNT [Botox] used for?

OnabotulinumtoxinA 145 UNT [Botox] is indicated for Cervical dystonia, Blepharospasm, Strabismus, Chronic migraine, Severe primary axillary hyperhidrosis.

Who makes OnabotulinumtoxinA 145 UNT [Botox]?

OnabotulinumtoxinA 145 UNT [Botox] is developed and marketed by Beth Israel Deaconess Medical Center (see full Beth Israel Deaconess Medical Center pipeline at /company/beth-israel-deaconess-medical-center).

Is OnabotulinumtoxinA 145 UNT [Botox] also known as anything else?

OnabotulinumtoxinA 145 UNT [Botox] is also known as BOTOX.

What drug class is OnabotulinumtoxinA 145 UNT [Botox] in?

OnabotulinumtoxinA 145 UNT [Botox] belongs to the Botulinum toxin class. See all Botulinum toxin drugs at /class/botulinum-toxin.

What development phase is OnabotulinumtoxinA 145 UNT [Botox] in?

OnabotulinumtoxinA 145 UNT [Botox] is FDA-approved (marketed).

What are the side effects of OnabotulinumtoxinA 145 UNT [Botox]?

Common side effects of OnabotulinumtoxinA 145 UNT [Botox] include Headache, Neck pain, Injection site pain, Muscle weakness, Eyelid ptosis, Diplopia.

What does OnabotulinumtoxinA 145 UNT [Botox] target?

OnabotulinumtoxinA 145 UNT [Botox] targets SNAP-25 (synaptosome-associated protein of 25 kDa) and is a Botulinum toxin.

Related